Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia

Completed · Phase 4 · Has a placebo group

Conditions studied: Schizophrenia, Schizoaffective Disorder

In brief

This is a 24-week, randomized, double-blind, placebo-controlled trial of exenatide weekly injection (2mg per dose) as an adjunctive therapy in 70 schizophrenia subjects to examine exenatide's effects on negative symptoms and cognition.

Key facts

Study ID
NCT02417142
Run by
University of Massachusetts, Worcester
People needed
70
Starts
2014-09-01
Expected to finish
2020-07-01
Last updated by the study team
2022-01-14

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.